| Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia L Falchi, MJ Keating, EM Marom, MT Truong, EJ Schlette, RL Sargent, ... Blood, The Journal of the American Society of Hematology 123 (18), 2783-2790, 2014 | 148 | 2014 |
| A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma JE Amengual, R Lichtenstein, J Lue, A Sawas, C Deng, E Lichtenstein, ... Blood, The Journal of the American Society of Hematology 131 (4), 397-407, 2018 | 134 | 2018 |
| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 128 | 2020 |
| Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, ... Journal of clinical oncology 39 (28), 3109, 2021 | 125 | 2021 |
| Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial OA O'Connor, JK Lue, A Sawas, JE Amengual, C Deng, M Kalac, L Falchi, ... The Lancet Oncology 19 (2), 257-266, 2018 | 122 | 2018 |
| Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study OA O’Connor, L Falchi, JK Lue, E Marchi, C Kinahan, A Sawas, C Deng, ... Blood, The Journal of the American Society of Hematology 134 (17), 1395-1405, 2019 | 117 | 2019 |
| Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study L Falchi, H Ma, S Klein, JK Lue, F Montanari, E Marchi, C Deng, HA Kim, ... Blood, The Journal of the American Society of Hematology 137 (16), 2161-2170, 2021 | 105 | 2021 |
| Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a … U Vitolo, A Chiappella, E Angelucci, G Rossi, AM Liberati, MG Cabras, ... haematologica 94 (9), 1250, 2009 | 93 | 2009 |
| Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin, MA Perales, M Scordo, ... Blood advances 4 (19), 4669-4678, 2020 | 87 | 2020 |
| Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies R Stuver, GL Shah, NS Korde, LE Roeker, AR Mato, CL Batlevi, DJ Chung, ... Cancer Cell 40 (6), 590-591, 2022 | 83 | 2022 |
| Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors L Falchi, HM Kantarjian, X Wang, D Verma, A Quintás‐Cardama, ... American journal of hematology 88 (12), 1024-1029, 2013 | 83 | 2013 |
| The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience L Laurenti, M Tarnani, I Nichele, S Ciolli, A Cortelezzi, F Forconi, D Rossi, ... American journal of hematology 86 (12), 1007-1012, 2011 | 65 | 2011 |
| The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review D Kc, L Falchi, S Verstovsek Annals of hematology 96, 1595-1604, 2017 | 64 | 2017 |
| Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia L Falchi, C Vitale, MJ Keating, S Lerner, X Wang, KYE Gbito, S Strom, ... Annals of Oncology 27 (6), 1100-1106, 2016 | 59 | 2016 |
| Tyrosine kinase inhibitors C Natoli, B Perrucci, F Perrotti, L Falchi, S Iacobelli Current Cancer Drug Targets 10 (5), 462-483, 2010 | 57 | 2010 |
| Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities L Falchi, SA Vardhana, GA Salles Blood 141 (5), 467-480, 2023 | 55 | 2023 |
| The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy L Falchi, S Verstovsek, F Ravandi‐Kashani, HM Kantarjian Cancer 122 (8), 1160-1168, 2016 | 45 | 2016 |
| High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy L Falchi, A Sawas, C Deng, JE Amengual, DS Colbourn, EA Lichtenstein, ... Journal of hematology & oncology 9, 1-4, 2016 | 44 | 2016 |
| Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era L Falchi, HM Kantarjian, S Verstovsek Leukemia 31 (9), 1845-1854, 2017 | 42 | 2017 |
| The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review P Boddu, L Falchi, C Hosing, K Newberry, P Bose, S Verstovsek Leukemia research 58, 14-22, 2017 | 40 | 2017 |
Alessandra FerrajoliVerified email at mdanderson.org
